Advertisement


Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: KEYNOTE-522 Trial of Pembrolizumab Plus Chemotherapy

ESMO 2019 Congress

Advertisement

Peter Schmid, MD, PhD, of Queen Mary University of London Barts Cancer Institute, discusses pathologic complete response data from a phase III study of pembrolizumab/chemotherapy vs placebo/chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as 6-month adjuvant treatment for early triple-negative breast cancer (Abstract LBA8).



Related Videos

Gynecologic Cancers

Mansoor R. Mirza, MD, and Robert L. Coleman, MD, on Integrating Velaparib With Chemotherapy and Maintenance Therapy in Gynecologic Cancers

Mansoor R. Mirza, MD, of Copenhagen University Hospital, and Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, discuss phase III study findings, wh...

Breast Cancer
Immunotherapy

Sherene Loi, MD, PhD, and Leisha A. Emens, MD, PhD, on HER2-Positive Breast Cancer: KATE2 Study of Atezolizumab/Trastuzumab Emtansine

Sherene Loi, MD, PhD, of Peter MacCallum Cancer Centre at the University of Melbourne, and Leisha A. Emens, MD, PhD, of UPMC Hillman Cancer Center, discuss o...

Bladder Cancer
Immunotherapy

Thomas Powles, MD, PhD, and Enrique Grande, MD, PhD, on Urothelial Carcinoma: Atezolizumab and Platinum-Based Chemotherapy

Thomas Powles, MD, PhD, of Queen Mary University of London, and Enrique Grande, MD, PhD, of MD Anderson Cancer Center, Madrid, discuss findings of the phase ...

Hepatobiliary Cancer

Ghassan K. Abou-Alfa, MD, MBA, on Cholangiocarcinoma: ClarIDHy Trial of Ivosidenib vs Placebo

Ghassan K. Abou-Alfa, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings showing improvement in progression-free survival among patients w...

Pancreatic Cancer

Volker Kunzmann, MD, on Advanced Pancreatic Cancer: Findings on nab-Paclitaxel/Gemcitabine and FOLFIRINOX

Volker Kunzmann, MD, of the University of Würzburg/Comprehensive Cancer Center Mainfranken, discusses the final results of a phase II multicenter trial on the conversion rate...

Advertisement

Advertisement



Advertisement